Results 11 to 20 of about 45,428 (223)

Development of a Macrophage-Based ADCC Assay [PDF]

Vaccines, 2021
Fc-dependent effector functions are an important determinant of the in vivo potency of therapeutic antibodies. Effector function is determined by the combination of FcRs bound by the antibody and the cell expressing the relevant FcRs, leading to antibody-dependent cellular cytotoxicity (ADCC).
Melissa B. Uccellini, Sadaf Aslam, Sean T. H. Liu, Fahmida Alam, Adolfo García-Sastre   +4 more
openaire   +3 more sources

MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma

OncoImmunology, 2022
The major histocompatibility complex-class I chain related proteins A and B (MICA/B) is upregulated because of cellular stress and MICA/B shedding by cancer cells causes escape from NKG2D recognition favoring the emergence of cancers. Cholangiocarcinoma (
Barbara Oliviero, Stefania Varchetta, Dalila Mele, Greta Pessino, Roberta Maiello, Monica Falleni, Delfina Tosi, Matteo Donadon, Cristiana Soldani, Barbara Franceschini, Guido Torzilli, Gaetano Piccolo, Matteo Barabino, Enrico Opocher, Marcello Maestri, Stefano Bernuzzi, Kai W. Wucherpfennig, Mario U. Mondelli, Stefania Mantovani   +18 more
doaj   +1 more source

Modulation of anti-tumour immunity by XPO1 inhibitors [PDF]

Exploration of Targeted Anti-tumor Therapy
Exportin-1 (XPO1) is a nuclear export protein that, when overexpressed, can facilitate cancer cell proliferation and survival and is frequently overexpressed or mutated in cancer patients.
Jack G. Fisher, Laura G. Bartlett, Trinayan Kashyap, Christopher J. Walker, Salim I. Khakoo, Matthew D. Blunt   +5 more
doaj   +1 more source

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. [PDF]

, 2017
BackgroundThe CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Amaya-Chanaga, Carlos I, Amine, Ale-Ali, Castro, Januario E, Choi, Michael Y, Fantin, Valeria R, Gu, Yin, Hallin, Max, Huser, Nanni, Kashyap, Manoj K, Kipps, Thomas J, Kumar, Deepak, Lindquist, Kevin, Liu, Shu-Hui, Pernasetti, Flavia, Rassenti, Laura Z, Simmons, Brett, Smeal, Tod, Yafawi, Rolla, Zhang, Cathy   +18 more
core   +4 more sources

Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies

eLife, 2021
A prerequisite for the design of an HIV vaccine that elicits protective antibodies is understanding the developmental pathways that result in desirable antibody features. The development of antibodies that mediate antibody-dependent cellular cytotoxicity
Laura E Doepker, Sonja Danon, Elias Harkins, Duncan K Ralph, Zak Yaffe, Meghan E Garrett, Amrit Dhar, Cassia Wagner, Megan M Stumpf, Dana Arenz, James A Williams, Walter Jaoko, Kishor Mandaliya, Kelly K Lee, Frederick A Matsen IV, Julie M Overbaugh   +15 more
doaj   +1 more source

Antitumor activity of an anti-CD98 antibody. [PDF]

, 2015
CD98 is expressed on several tissue types and specifically upregulated on fast-cycling cells undergoing clonal expansion. Various solid (e.g., nonsmall cell lung carcinoma) as well as hematological malignancies (e.g., acute myeloid leukemia) overexpress ...
Cairns, Belinda, Cantor, Joseph M, Chinn, Lawrence, Duey, Dana, Ginsberg, Mark H, H van der Horst, Edward, Hayes, Gregory M, Levashova, Zoia, Lippincott, John, Tran, Hoang, Velilla, Timothy, Zachwieja, Joseph   +11 more
core   +1 more source

Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients [PDF]

, 2015
Natural Killer (NK) cells are a key component of tumor immunosurveillance and thus play an important role in rituximab-dependent killing of lymphoma cells via an antibody-dependent cellular cytotoxicity (ADCC) mechanism.
Battella, Simone, Cecere, Francesca, DI NAPOLI, Arianna, Eleonora, Alma, LA SCALEIA, Raffaella, M., Christina Cox, Mainiero, Fabrizio, Monarca, Bruno, Palmieri, Gabriella, Pelliccia, Sabrina, Porzia, Alessandra, Ruco, Luigi, Santoni, Angela, Zingoni, Alessandra   +13 more
core   +1 more source

Combination Strategies to Enhance Antitumor ADCC [PDF]

Immunotherapy, 2012
The clinical efficacy of monoclonal antibodies as cancer therapeutics is largely dependent upon their ability to target the tumor and induce a functional antitumor immune response. This two-step process of ADCC utilizes the response of innate immune cells to provide antitumor cytotoxicity triggered by the interaction of the Fc portion of the antibody ...
Holbrook E, Kohrt, Roch, Houot, Aurélien, Marabelle, Hearn Jay, Cho, Keren, Osman, Matthew, Goldstein, Ronald, Levy, Joshua, Brody   +7 more
openaire   +2 more sources

Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines

npj Vaccines, 2022
Zoster vaccines generate antibody responses against varicella-zoster virus (VZV). We compared antibody-dependent cell cytotoxicity (ADCC) elicited by zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV).
Seong Yeon Park, Myron J. Levin, Jennifer Canniff, Michael Johnson, D. Scott Schmid, Adriana Weinberg   +5 more
doaj   +1 more source

A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors

OncoImmunology, 2017
The use of monoclonal antibodies (mAb) for the diagnosis and treatment of malignancies is acquiring an increasing clinical importance, thanks to their specificity, efficacy and relative easiness of use. However, in the context of Epstein-Barr virus (EBV)-
Riccardo Turrini, Anna Merlo, Debora Martorelli, Damiana Antonia Faè, Roberta Sommaggio, Isabella Monia Montagner, Vito Barbieri, Oriano Marin, Paola Zanovello, Riccardo Dolcetti, Antonio Rosato   +10 more
doaj   +1 more source